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Abstract
Background: The human ATP-binding cassette, subfamily B, member 11 (ABCB11) gene encodes the bile salt
export pump, which is exclusively expressed at the canalicular membrane of hepatocytes. A frequent variant in
the coding region, c.1331 T>C, leading to the amino acid exchange p.V444A, has been associated with altered
serum bile salt levels in healthy individuals and predisposes homozygous carriers of the [C] allele for obstetric
cholestasis. Recently, elevated bile salt levels were shown to be significantly associated with rates and risk of
cirrhosis in patients with chronic hepatitis C virus (HCV) infection treated with pegylated interferon-α2 and ribavirin,
suggesting a potential role for bile salt levels in HCV treatment outcomes and in the fibrogenic evolution of
HCV-related liver disease. The aim of this study was to investigate a possible association of ABCB11 c.1331 T>C
with hepatitis C virus (HCV) infection and fibrosis stages as assessed by non-invasive transient elastography in a
German cohort of patients.
Methods: ABCB11 c.1331 T>C genotype was determined by allelic discrimination assay in 649 HCV infected
cases and 413 controls. Overall, 444 cases were staged for fibrotic progression by measurement of liver stiffness.
Results: Homo- or heterozygous presence of the frequent [C] allele was associated with HCV positivity (OR=1.41,
CI=1.02 - 1.95, p=0.037). No association was detectable between the ABCB11 c.1331 T>C genotype and increased
liver stiffness.
Conclusions: Our data confirm that homozygous presence of the major [C] allele of ABCB11 c.1331 T>Ci sa
genetic susceptibility factor for HCV infection, but not for liver fibrosis.
Background
Hepatitis C virus (HCV) is one of the most common
causes of fibrotic liver disease. It is estimated that there
are 5 million carriers in Europe, and up to 500.000
chronically HCV-infected people in Germany [1]. These
individuals are at high risk of developing progressive
liver disease, including cirrhosis and hepatocellular car-
cinoma [2,3]. Genetic factors influence susceptibility to
HCV infection but also progression of the disease. Due
to the viral life cycle and its reliance on the infected cell,
host genetic factors are likely to exert a strong influence
on these processes. This has been shown for example
in a study compromising Irish women infected with an
HCV-contaminated anti-D immunoglobulin acquired
from the same acutely infected person [4,5]. The analysis
of liver samples acquired in average almost two decades
after the infection showed a highly variable disease pro-
gression, which was apparently not affected by the type of
the hepatitis C virus itself but by the host genetic back-
ground and lifestyle [4,5]. A number of genetic studies
have reported associations of variants in candidate genes
such as tumor necrosis factor [6-8], interleukin 10 [9],
HLA subtypes [10-12] and CC chemokine receptor 5 [13]
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Huang et al. [14] used a machine learning approach and
two independent Caucasian cohorts to identify a seven-
gene signature that allows better prognosis of fibrosis pro-
gression in HCV infected individuals than established
clinical parameters. This study and the follow-up by Mar-
colongo et al. in an Italian population [15] illustrate the
feasibility of genetic risk assessment for cirrhosis predic-
tion. They also accentuate the need to identify additional
genetic factors that contribute towards HCV susceptibility
and subsequent fibrotic progression. A comprehensive
map of cirrhosis-associated variants might permit verifica-
tion of interacting and modifying loci in selected patient
groups, which would in turn improve the predictive
values of polygenic cirrhosis risk scores.
Previously a common, non-conservative polymorphism
c.1331 T>C (p.V444A) in the hepatobiliary bile salt
transporter ABCB11 (also known as bile salt export
pump, BSEP) was identified as a risk factor for
cholestatic liver diseases, in particular drug-induced cho-
lestasis [16] and intrahepatic cholestasis of pregnancy
[17,18]. The human bile salt export pump represents
the central canalicular transporter of bile salts from
hepatocytes into the bile canaliculus [19,20]. In normal
conditions, ABCB11 together with other hepatobiliary
proteins (i.e. ABCB4 and ABCG5/8 transporting phos-
pholipids and sterols into bile, respectively) maintain
proper concentrations of biliary constituents. This, in
turn, preserves bile flow and minimises the toxic proper-
ties of biliary components. Interestingly, the analysis
of hepatobiliary transporter expression has demon-
strated that the functional effect of the p.A444V poly-
morphism is due to markedly lower expression of
ABCB11 [21,22] rather than impaired function of the
protein [16].
Lately two reports have underscored an association
between the c.1331 T>C variant and both response to
antiviral treatment [23] and the presence of cirrhosis
in patients with chronic HCV infection [24]. The ana-
lysis of 151 individuals treated with ribavirin and pegy-
lated interferon demonstrated that those carrying the
genotype [TT] and infected with HCV genotypes 2 or 3
show increased sustained virological response (SVR)
rates as compared to [CC] individuals [23]. Additionally,
the [CC] genotype has been reported to increase the
risk of developing liver cirrhosis in chronic HCV infec-
tion [24].
To validate and extend previous results concerning
possible associations of the common polymorphism
c.1331 T>C in the bile salt export pump with HCV in-
fection and fibrosis progression, we analysed its geno-
type distribution in a larger cohort of 649 patients with
chronic HCV infection, in 444 of whom liver fibrosis
was staged non-invasively by transient liver elastography.
Methods
Patients
Overall, we included 649 patients with chronic HCV in-
fection. The cohort consisted of two ethnically matched
subgroups of patients: 487 patients with active chronic
HCV infection were prospectively recruited at the
Department of Medicine I of the University Hospital
Bonn. Patients were included in the study if they were
positive for anti-HCV antibodies and had detectable
HCV-RNA in serum. Patients with other viral infections
(HBV, HDV, HIV) or chronic liver diseases were
excluded. Baseline clinical characteristics of the studied
cohort have been published previously [25] and are sum-
marised in Table 1. In addition, we included 162
treatment-naïve HCV patients recruited at the Depart-
ment of Medicine II of the Saarland University Hospital
in Homburg. However, since there were incomplete phe-
notyping data in terms of liver stiffness measurements,
this group of patients was included only in the analysis of
HCV-positive versus HCV-negative individuals. Patients
without TE were also eligible for the study when they
presented with overt signs of liver cirrhosis such as
ascites, signs of portal hypertension, or coagulopathy. In
addition, 413 HCV-negative individuals were recruited
from the outpatient clinic of the Department of Medi-
cine I of the University Hospital Bonn. The most
frequent aetiologies of liver damage were alcohol (97),
non-alcoholic fatty liver disease (63), chronic hepatitis B
virus infection (73), autoimmune hepatitis (29),
haemochromatosis (26), primary biliary cirrhosis (23),
and primary sclerosing cholangitis (13). The median age
of the HCV-negative individuals was 53 years (range 18-
88), and the gender ratio was 1,4:1. All patients gave
written informed consent. The study was approved by in-
dependent ethics committees at the Universities of Bonn
and Saarland.
Table 1 Patient cohort characteristics
Factor Bonn cohort Homburg cohort
(n=487) (n=162)
Age (years) 48 (19-83) 49 (21-79)
Gender
Male 315 (64.7%) 75 (46.3%)
Female 172 (35.3%) 87 (53.7%)
BMI (kg/m
2) 24.2 (14.8 - 39.8) 25.7 (17.0 - 43.0)
TE (kPa) 7.1 (2.7 - 75.0) n.a.
HCV genotypes
HCV 1 170 (46%) 139 (86%)
HCV non-1 199 (54%) 23 (14%)
unknown 118
Continuous variables are presented as medians and ranges.
Abbreviations: BMI, body mass index; n. a., not available; TE, transient
elastography.
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In total, 444 patients with chronic HCV infection were
examined by transient elastography (TE). Although liver
biopsy represents a “gold standard” of quantifying liver
status in patients with chronic liver diseases, we have
lately shown that TE is a feasible phenotyping method in
genetic studies aiming at identification of novel variants
affecting liver fibrogenesis [25]. Hence, in our current
study we determined liver stiffness by TE. In brief, the
tip of the probe transducer was placed on the skin be-
tween the rib bones at the level of the right lobe of the
liver. The measurement depth ranged between 25 and
65 mm below the skin surface. In case of ascites, elasto-
graphy was preceded by large-volume paracentesis. Ten
measurements were performed in each individual, and
subsequently the median value was taken as representa-
tive. Patients were assigned to different fibrosis stages
according to TE results, using previously published cut-
off values; in particular, patients with TE results≥13.0
kPa or overt clinical signs were diagnosed to suffer from
liver cirrhosis, since TE cut-offs in this range were
demonstrated to be optimal for the diagnosis of cirrhosis
[26].
Genotyping
Genomic DNA was isolated from EDTA anti-coagulated
blood using the membrane based QIAamp DNA extrac-
tion protocol (Qiagen, Hilden, Germany). DNA concen-
trations were determined fluorometrically (Bio-Rad
Laboratories, Hercules, CA, USA), employing the dye
PicoGreen (Molecular Probes, Leiden, Netherlands).
The ABCB11 polymorphism c.1331 T>C (rs2287622)
[17,22-24] was genotyped using solution-phase hybridi-
zation reactions with 5'-nuclease and fluorescence detec-
tion (TaqMan assays) on the 7300 Real-Time PCR System
(Applera, Norwalk, CT, USA). PCR reactions contained
20 ng genomic DNA, 1× TaqMan Universal Master Mix,
900 nM of each primer, and 200 nM of VIC-labeled and
FAM-labeled probes in 25 μl-reactions. Amplification
conditions were 95°C for 10 min, followed by 40 cycles at
92°C for 15 s, and 60°C for 1 min. Primers and probes are
available from the Applera database (http://www.applied-
biosystems.com/).
Statistics
Data are given as means±SD, unless stated otherwise.
Kolmogorov-Smirnov’s test was used to determine
whether data had a normal distribution.
Exact tests were performed to ensure consistency of
the genotyping results with Hardy-Weinberg equilibrium
(HWE) (http://ihg2.helmholtz-muenchen.de/cgi-bin/hw/
hwa1.pl). Association case–control analysis was per-
formed to investigate the role of the ABCB11 variant in
the susceptibility to HCV infection. Logistic regression
analysis for the presence of cirrhosis was performed with
SPSS 18.0 (SPSS, Munich, Germany) and DATADESK
(Data Description, Ithaca, NY, USA). To compensate for
multiple testing (5 parameters), a P-value below 0.018
was considered significant in regression analysis.
Results
Carriers of the ABCB11 c.1331 C allele are at increased
risk of HCV infection
Overall, 649 patients with active chronic HCV infection
and 413 control individuals were genotyped. We did not
observe a significant difference in allele frequencies
between patients and controls (P=0.06). Interestingly,
genotype analysis presented in Table 2 demonstrates that
homo- and heterozygous carriers of the risk allele [C]
were 1.4 times as likely to suffer from active HCV infec-
tion than patients with genotype [TT] (P=0.037).
ABCB11 c.1331 T>C variant does not increase the risk of
liver fibrosis or cirrhosis in chronic hepatitis C patients
To assess a potential impact of the ABCB11 c.1331 risk
genotype [CC] on cirrhosis, we performed univariate
and multivariate logistic regression analyses. No signifi-
cant correlation was detected between the presence
of cirrhosis (TE≥13kPa) and the presence of the [CC]
genotype in patients (P=0.925). The only factor signifi-
cantly associated with the presence of cirrhosis
in multivariate analysis was the age of the patients
(P=0.006) (Table 3).
Figure 1 illustrates that scatterplot analysis is indica-
tive of a higher frequency of individuals with more
Table 2 Genotyping results for ABCB11 c.1331 T>C from
patients and controls
ABCB11 p.V444A
(c.1331 T>C) alleles/
genotypes
Counts (frequencies) of alleles/genotypes
Cases (N=649) Controls (N=413)
[T] 511 (0.39) 359 (0.43)
[C] 787 (0.61) 467 (0.57)
[TT] 97 (0.15) 82 (0.20)
[TC] 317 (0.49) 195 (0.47)
[CC] 235 (0.36) 136 (0.33)
Tests for association chi
2 P
Allele frequency difference 3.50 0.061
Armitage’s trend test 3.49 0.062
OR statistics OR (95% CI) P
[C] ↔ [T] 1.18 (0.99 - 1.41) 0.061
[CC] ↔ [TT] 1.46 (1.02 - 2.10) 0.040
[CC+CT] ↔ [TT] 1.41 (1.02 - 1.95) 0.037
Patients with HCV infections are regarded as cases.
Abbreviations: A, alanine; ABCB11, ATP-binding cassette, subfamily B, member
11; CI, confidence interval; OR, odds ratio; p, protein (amino acid number),
V, valine.
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genotypes [CC] or [CT] as compared to homozygous
[TT] individuals. This observation does not reach statis-
tical significance in numerical comparison due to the
low numbers of homozygous [TT] carriers.
Discussion
The present study shows that a common variant in the
human bile salt export pump ABCB11 is overrepresented
in patients with HCV infection. The reason underlying
this observation is speculative, although it might be
caused by differences in spontaneous recovery from in-
fection and sustained virological response (SVR) rates, as
was observed in patients bearing HCV genotypes 2 and 3
in a previous study: Iwata et al. [23] were able to show
that the effect might be mediated by serum bile salt con-
centrations, with low levels (< 8 μM) being associated
with SVR in their cohort. This is not the first time that
bile salts or genes involved in their metabolism have
been implicated in the pathogenesis of HCV infec-
tion. Ursodeoxycholic acid has been previously
proven in various trials to be beneficial in patients
suffering from liver damage due to chronic infection,
albeit not via modulation of SVR [27-29]. Contrast-
ingly, increased serum levels of bile salts are asso-
ciated with negative outcomes in HCV therapy [30].
The observed association between a polymorphism
that impinges bile salt transport from the hepatocyte
into the canaliculus offers an explanation of this
conundrum: Viral replication might be boosted in-
side the hepatocyte by relatively high bile salt con-
centrations [30]. A variant of the bile salt export
pump with lower expression level resulting in
reduced transport activity, such as the common [C]
allele of c.1331 T>C, might lead to transient
increases in hepatocellular bile salt concentration,
depending on the efficiency of the sinusoidal import.
Ursodeoxycholic acid as rather weak FXR agonist is
known to increase the expression and activity of bile salt
transporters by transcriptional as well as multiple post-
transcriptional mechanisms and to contribute to SHP-
mediated inhibition of bile salt synthesis [31,32]. In vitro
experiments using HCV replicon-harboring cells have
shown that the impact of bile salts on HCV replication
is mediated by the action of FXR rather than via direct
effects. FXR antagonisation by guggulsterone blocked
the bile salt-induced up-regulation of virus replication;
furthermore, guggulsterone inhibited basal levels of
HCV replication [30,33]. Hence, it is possible that HCV
"hijacks" or uses transcriptional activation via FXR.
Whatever the mode of action by which HCV takes ad-
vantage of FXR signalling, it appears to be advantageous
for the hepatotropic virus to use central functions of
hepatocytes for its own end.
HCV replication is tightly linked to lipid metabolism,
and bile salts are crucially involved in fat absorption and
transport. This reinforces the key roles of bile salt
responsive regulatory molecules such as FXR and TGR5 as
potential host factors modulating HCV replication, not ne-
cessarily through direct effect of bile salts but via feedback
regulation of lipid metabolism. In infected cells, HCV core
protein accumulates on the surface of lipid droplets [34,35].
Other functional proteins, such as RNA binding replicase
NS5A, are targeted to lipid droplets, and this targeting
appears to be crucial for HCVassembly [36]. A recent com-
bined transcriptome and proteome analysis revealed the
impact of HCV infection on previously unknown metabolic
pathways, particularly an increase in cellular cholesterol
and free fatty acid levels [37]. One possible reason for this
"metabolic reprogramming" might be the dependency of
HCV replication on lipid metabolism as outlined above.
Considering the central role of ABCB11 in bile flow, it is
not inconceivable to conclude that common variants of this
Table 3 Univariate and multivariate analysis of the
presence of cirrhosis (TE≥13kPa)
Univariate analysis:
Parameter OR 95% CI P value
Age (>40 vs ≤40 years) 2.405 1.311 - 4.411 0.005
Gender (male vs. female) 1.466 0.914 - 2.350 0.131
HCV genotype (1 vs 2/3) 1.263 0. 771-2.070 0.353
BMI (>25 vs ≤25 kg/m
2) 1.676 1.038 - 2.707 0.034
ABCB11 (CC vs CT+TT) 1.022 0.650 - 1.608 0.925
Multivariate analysis:
Parameter OR 95% CI P value
Age (>40 vs ≤40 years) 2.714 1.341 - 5.496 0.006
BMI (>25 vs ≤25 kg/m
2) 1.622 1.000 - 2.632 0.050
Figure 1 Scatter plot of TE results [kPa] for ABCB11 c.1331 T>C
genotypes (n=444).
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terol levels. In fact, a meta-analysis of genome-wide associ-
ation scans supports this reasoning [38], thus providing
further evidence for another potential connection
between bile salt transport and HCV replication. The
results from our study are indicative of a role for the major
allele of the ABCB11 c.1331 variant in conveying suscepti-
bility to persistent HCV infection, enhancing this link.
Iwata and colleagues observed an overrepresentation
of the [C] allele at ABCB11 c.1331 in HCV patients
(n=206) compared with controls (n=110) in the Swiss
Hepatitits C cohort (allelic frequency=62.9%), although
no significant difference in median bile salt serum con-
centration could be detected between bearers of homo-
zygous [C] or [T] alleles [24]. However, a comparison of
fibrosis scores from 178 patients revealed a skewed dis-
tribution: Carriers of homozygous [C] allele were over-
represented among cirrhotic patients, and the [CC]
genotype was an independent risk factor for cirrhosis in
multivariate analysis (p=0.010).
Our investigations into a connection between ABCB11
c.1331 T>C and liver stiffness as measured by TE
(Fibroscan) did not reveal any significant associations.
This may be due to methodolocial differences in asses-
sing fibrosis/cirrhosis [25,26]. Scatterplot analysis of TE
results from the different genotypes seems to indicate a
prevalence of lower values in patients bearing the [TT]
genotype (Figure 1), which would be in agreement with
the data from the Swiss cohort, but the numbers of
homozygous carriers of the minor allele in our cohort
were too low to reach statistical significance.
Cirrhosis was significantly associated with the age of
patients (p=0.006), which may reflect longer duration of
chronic HCV infection. However, since the exact time point
of infection was unknown in the majority of our patients,
we used age as surrogate marker in our statistical analyses.
Interestingly, when comparing allelic distribution in our
cohort with figures from the Swiss Hepatitis C cohort [24],
ABCB11 c.1331 T>C is equally skewed towards an
overrepresentation of the [C] allele among British
patients with non-alcoholic fatty liver disease in the
study by Iwata et al., pointing towards a potential role of
ABCB11 via its impact on lipid metabolism rather than
viral replication. The development of diet-induced obes-
ity and hypercholesterolemia following hepatocye-
specific overexpression of ABCB11 in mice is a pointer
in the same direction [39].
Based on the assumption that populations from both the
Swiss study and our cohort are from a similar ethnic back-
ground, we speculate that the major [C] allele
of ABCB11 c.1331 T>C might be a high-frequency
low-risk contributor towards susceptibility for various
complex liver diseases triggered by external stimuli and
involving lipid metabolism [40].
Conclusions
Individuals bearing the homozygous [C] allele at
ABCB11 c.1331 T>C are overrepresented in a German
cohort of HCV patients. This variant has been linked to
lower expression of the resulting ABCB11 protein, which
supports a role of bile salts in the hepatocytes' response
to HCV infection.
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